title: A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.
authors.affiliation: R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania 19477.
authors.forename: A B
authors.initials: AB
authors.lastname: Reitz
authors.forename: D J
authors.initials: DJ
authors.lastname: Bennett
authors.forename: P S
authors.initials: PS
authors.lastname: Blum
authors.forename: E E
authors.initials: EE
authors.lastname: Codd
authors.forename: C A
authors.initials: CA
authors.lastname: Maryanoff
authors.forename: M E
authors.initials: ME
authors.lastname: Ortegon
authors.forename: M J
authors.initials: MJ
authors.lastname: Renzi
authors.forename: M K
authors.initials: MK
authors.lastname: Scott
authors.forename: R P
authors.initials: RP
authors.lastname: Shank
authors.forename: J L
authors.initials: JL
authors.lastname: Vaught
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000138:chemical synthesis / Q000378:metabolism* / Q000494:pharmacology; D004285:Dogs; D006801:Humans; D015394:Molecular Structure; D010879:Piperazines / Q000138:chemical synthesis / Q000378:metabolism* / Q000494:pharmacology; D020891:Raclopride; D051381:Rats; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D050637:Receptors, Dopamine D3; D011985:Receptors, Serotonin / Q000378:metabolism*; D012457:Salicylamides / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; C493593:DRD3 protein, human; C493595:Drd3 protein, rat; D010879:Piperazines; D011942:Receptors, Adrenergic, alpha; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D011985:Receptors, Serotonin; D012457:Salicylamides; D020891:Raclopride; C086897:mazapertine succinate